Evaluation of Congestion in Outpatients with Chronic Heart Failure CHF-COV Study

What this Trial Is About

Researchers are evaluating markers of congestion in patients with chronic heart failure (HF), a leading cause of hospitalization and death in older adults. This study aims to identify clinical, biological, and ultrasound markers measured during scheduled consultations or day hospitalizations that are linked to the risk of death or hospitalization due to acute heart failure within 24 months. Understanding these markers could help improve monitoring and management of chronic HF. Participants will undergo a clinical exam focused on congestion, including the use of specific scoring systems, and several types of Doppler ultrasounds of the heart, lungs, peritoneum, jugular and renal veins, along with optional liver elastography. Blood samples will be taken for biological assessments and biobanking. Follow-up will be conducted by telephone at 3, 12, and 24 months after the initial visit. Patients will also complete a quality of life questionnaire at discharge and during follow-ups. During the study, participants will be closely monitored through clinical exams, ultrasounds, laboratory tests, and questionnaires assessing quality of life. The primary outcomes measured are the rates of all-cause death and hospitalization for acute heart failure over 24 months. Secondary outcomes include cardiovascular hospitalizations, death rates, heart function class, various blood markers, renal function, plasma volume, liver status, and patient quality of life. The study ensures ongoing safety monitoring through regular follow-ups and assessments over two years.

Chronic Heart Failure - COngestion eValuation